ForeSentia tumour molecular profile – comprehensive panel of 222 genes

What is the ForeSENTIA Pan-Cancer Plus Molecular Tumor Profiling Test – Comprehensive Panel of 222 Genes?

ForeSENTIA Pan-Cancer Plus is an advanced oncogenetic test that enables molecular profiling of cancer, identifying a wide range of genetic changes and genomic biomarkers such as microsatellite instability (MSI¹) and tumor mutational burden (TMB²). This allows for the application of targeted therapies tailored to the individual needs of the patient.

¹ MSI - Microsatellite Instability

² TMB - Tumor Mutational Burden

Who is the ForeSENTIA Pan-Cancer Plus Molecular Tumor Profiling Test – Comprehensive Panel of 222 Genes intended for?

The ForeSENTIA Pan-Cancer Plus test is dedicated to individuals diagnosed with malignant cancer. It is particularly recommended for:

• Patients who require genetic testing for qualification to targeted treatment.
• Patients with treatment resistance or cancer recurrence, who are seeking alternative therapeutic options, including immunotherapy.
• Patients who want to increase the chances of selecting effective treatment through biomarker testing related to immunotherapy.

How to prepare for the ForeSENTIA Pan-Cancer Plus Molecular Tumor Profiling Test – Comprehensive Panel of 222 Genes?

No special preparation is required for this test. You need to provide paraffin blocks of tissue material collected during the procedure (including slides). No doctor's referral is required.

You can perform the test within 3 months of its purchase (counting from the date indicated in the order confirmation).

How is the ForeSENTIA Pan-Cancer Plus Molecular Tumor Profiling Test – Comprehensive Panel of 222 Genes performed?

1. Contact our team – leave your details in the contact form. We will contact you within 2 business days and explain the next steps.

Actions before genetic testing of the tumor tissue:

• Purchase the histopathological evaluation service and send us the paraffin blocks, which are tissue samples collected during biopsy or surgery, preserved in formalin and embedded in paraffin.
• The material will undergo histopathological evaluation to determine the percentage of cancer cells and the possibility of genetic testing.
• After the positive evaluation of the material, the specialist will prepare the sample for genetic testing.

We also recommend reviewing the Patient Instruction, which explains in detail how the ForeSENTIA test is performed (you can find it in the Documents section).

2. Purchase the ForeSENTIA Pan-Cancer Plus test – choose the test online or at the Centrum Medyczne Damiana facility.

3. After purchasing the test, we will send the sample to the genetic laboratory.

4. Laboratory analysis – the sample will be sent for advanced genetic analysis at the Medicover Genetics laboratory.

5. You will receive the result after 30 days from the moment the sample reaches the laboratory. The test result will be sent to the previously provided email address.

6. FREE ONCOLOGICAL CONSULTATION – after receiving the test report, you can discuss the result with an oncologist within 3 months of receiving the result.

How long does it take to receive the result and how to interpret it?

The report of the performed test (in Polish) will be sent to the previously provided email address within 30 business days from the receipt of the sample at the laboratory.

Please note that the interpretation of genetic results depends on the patient's clinical picture.

After the test is completed, a comprehensive report will be prepared, containing a detailed interpretation and classification of detected genetic changes and biomarkers according to the latest guidelines. The report will also include current information on available therapeutic options. This will allow precise treatment tailoring based on the genetic profile of the patient's tumor.

The test report includes:

• Evaluation of the status of immunotherapy biomarkers MSI and TMB

The microsatellite instability (MSI) status and the tumor mutational burden (TMB) result are presented along with currently FDA³/EMA⁴-approved immunotherapies.

• Results of the genetic change analysis

Identified variants of strong, potential, and uncertain significance are reported along with FDA/EMA-approved or NCCN⁵-recommended targeted therapies, including:
Therapies approved for the patient's indications
Therapies included in NCCN guidelines
Variants associated with lack of response to treatment

• Eligibility for clinical trials

The report includes ongoing clinical trials, expanding the therapeutic options available to the patient. The results are presented in a comprehensive and clear manner, providing essential information when making therapeutic decisions.

³ FDA – Food and Drug Administration

⁴ EMA – European Medicines Agency

⁵ NCCN – National Comprehensive Cancer Network®

How can the ForeSENTIA Pan-Cancer Plus tumor molecular profile test - comprehensive panel of 222 genes help you?

The ForeSENTIA Pan-Cancer Plus test provides key information that supports the oncology treatment process:

• Simultaneous analysis of clinically relevant genetic changes and immunotherapy biomarkers (MSI and TMB) within one test.
• Includes genes recommended by international oncology societies and considered as criteria in ongoing clinical trials.
• Assesses tumor-agnostic biomarkers, which increases the range of possible applications.
• Supports selection of targeted therapies, including immunotherapy, which effectively target cancer cells with less impact on healthy tissues.
• Helps avoid ineffective treatments that could unnecessarily burden the patient's body.
• Informs about available clinical trials that the patient may qualify for, increasing the chances for modern, often innovative therapies.

Why should you choose the ForeSENTIA Pan-Cancer Plus tumor molecular profile test - comprehensive panel of 222 genes?

The ForeSENTIA test is a comprehensive genetic diagnostic tool that allows precise determination of a tumor's molecular profile. Thanks to broad genetic analysis, it helps in selecting the optimal therapy and increases the chances of effective treatment.

Learn more and schedule your test!

The test is performed by Medicover Genetics (Cyprus) – a laboratory with years of experience.

Technical details regarding the NGS test:

A unique process combining proprietary Targeted Capture Enrichment Technology, next-generation sequencing (NGS), and innovative bioinformatics algorithms ensures precise detection of genetic variants within the ForeSENTIA Pan-Cancer Plus test.

The ForeSENTIA Pan-Cancer Plus test detects clinically significant genetic changes, including:

• single nucleotide variants (SNVs);
• insertions and deletions (INDELs);
• copy number alterations (CNAs);
• rearrangements.

The test analyzes the entire exons of 222 genes⁶.

The ForeSENTIA test also assesses immunotherapy biomarkers – microsatellite instability (MSI) and tumor mutational burden (TMB).

⁶ Except for regions containing repeats, sequences with high homology (pseudogenes, segmental duplications), or regions with high/low GC content.

Genetic changes detected in the ForeSENTIA Pan-Cancer Plus test:

SNVs/INDELs

ABL1, ABL2, AKT1, AKT2, ALK, ANKRD26, APC, AR, ARAF, ASXL1, ATM, ATRX, B2M, BAP1, BARD1, BCL2, BCL6, BCOR, BCORL1, BCR, BMPR1A, BRAF, BRCA1, BRCA2, BRIP1, CALR, CBFB, CBL, CBLB, CBLC, CCND1, CCND2, CCND3, CCNE1, CD274, CD74, CDC25C, CDH1, CDK12, CDK4, CDK6, CDKN2A, CEBPA, CHEK2, CIC, CSF1R, CSF3R, CTLA4, CTNNB1, CUX1, CXCR4, DCK, DDR2, DDX41, DEK, DHX15, DICER1, DNMT3A, DUSP22, EGFR, EIF1AX, EPCAM, ERBB2, ERBB3, ERBB4, ERCC4, ERG, ESR1, ETNK1, ETV1, ETV4, ETV6, EWSR1, EZH2, FANCA, FBXW7, FGF13, FGF19, FGF2, FGF3, FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT3, FLT4, FOXA1, FOXL2, FOXO1, FRS2, FUBP1, GATA1, GATA2, GATA3, GNA11, GNAQ, GNAS, H3F3A, HDAC2, HOXB13, HRAS, IDH1, IDH2, IKZF1, IL3, INHA, INSRR, IRF4, JAK1, JAK2, JAK3, KDM6A, KDR, KEAP1, KIT, KMT2A, KMT2C, KMT2D, KRAS, LUC7L2, MALT1, MAP2K1, MAP2K2, MAP3K1, MDM2, MECOM, MET, MITF, MLH1, MLLT3, MPL, MRE11, MSH2, MSH6, MTOR, MUTYH, MYC, MYCN, MYD88, MYH11, MYOD1, NBN, NCOA3, NF1, NF2, NFE2L2, NOTCH1, NPM1, NRAS, NRG1, NTRK1, NUP214, NUTM1, PALB2, PARP1, PBX1, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PGR, PHF6, PIK3CA, PIK3CB, PIK3R1, PML, PMS2, POLD1, POLE, PPM1D, PPP2R1A, PTCH1, PTEN, PTPN11, RAD21, RAD51C, RAD51D, RAF1, RARA, RB1, RBBP6, RET, RNF43, RPS14, RUNX1, RUNX1T1, SETBP1, SF3B1, SH2B3, SLC29A1, SMAD4, SMARCA4, SMARCB1, SMC1A, SMC3, SMO, SOX10, SPOP, SRSF2, STAG2, STAT3, STAT5B, STK11, SUZ12, TCF3, TCL1A, TERT, TET2, TMPRSS2, TP53, TSC1, TSC2, U2AF1, VEGFA, VHL, WT1, XPO1, ZRSR2

CNAs

Codeletion 1p/19q, AKT1, ALK, AR, ATM, BRAF, BRCA1, BRCA2, CCND1, CD274, CDK4, CDKN2A, CHEK2, EGFR, ERBB2, ERBB3, ESR1, FGFR1, FGFR2, FGFR3, JAK2, KIT, KRAS, MDM2, MET, MYC, MYCN, NCOA3, NRAS, NRG1, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PTEN, RAF1, RB1, RET, SMAD4, TERT, TP53

Rearrangements

ALK, BRAF, CD74, FGFR1, FGFR2, FGFR3, NTRK1, NTRK2, NTRK3, NUTM1, PDGFRA, RET, ROS1, TMPRSS2

Where to perform the ForeSENTIA Pan-Cancer Plus tumor molecular profile test - comprehensive panel of 222 genes?

The ForeSENTIA Pan-Cancer Plus test is available at Centrum Medyczne Damiana facilities. Check locations and schedule your test!